Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Filings indexed 384 across all filing types
Latest filing 2020-01-28 Regulatory Filings
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings
2020-01-28 English
Regulatory Filings 2019
Regulatory Filings
2019-12-31 English
Regulatory Filings 2019
Regulatory Filings
2019-12-31 English
Regulatory Filings 2018
Regulatory Filings
2018-11-20 English
Regulatory Filings 2017
Regulatory Filings
2017-08-04 English
Regulatory Filings 2016
Regulatory Filings
2016-08-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.